Citigroup Inc C4 Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 103,968 shares of CCCC stock, worth $410,673. This represents 0.0% of its overall portfolio holdings.

Number of Shares

103,968

Previous 30,456 241.37%

Holding current value

$410,673

Previous $140,000 322.86%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$4.43 - $7.38 $325,658 - $542,518	73,512 Added 241.37%	103,968 $592,000
Q2 2024 Aug 12, 2024	SELL	$4.05 - $8.1 $3 Million - $6 Million	-740,272 Reduced 96.05%	30,456 $140,000
Q1 2024 May 10, 2024	BUY	$5.3 - $11.0 $3.37 Million - $6.99 Million	635,255 Added 468.92%	770,728 $6.3 Million
Q4 2023 Feb 09, 2024	BUY	$1.18 - $6.03 $91,543 - $467,801	77,579 Added 134.0%	135,473 $765,000
Q3 2023 Nov 09, 2023	BUY	$1.81 - $3.89 $71,480 - $153,623	39,492 Added 214.61%	57,894 $107,000
Q2 2023 Aug 10, 2023	BUY	$2.75 - $3.77 $46,703 - $64,025	16,983 Added 1196.83%	18,402 $50,000
Q1 2023 May 11, 2023	SELL	$3.1 - $9.02 $239,902 - $698,039	-77,388 Reduced 98.2%	1,419 $4,000
Q4 2022 Feb 09, 2023	SELL	$5.42 - $10.24 $136,995 - $258,826	-25,276 Reduced 24.28%	78,807 $464,000
Q3 2022 Nov 10, 2022	BUY	$8.03 - $12.77 $798,061 - $1.27 Million	99,385 Added 2115.47%	104,083 $913,000
Q2 2022 Aug 10, 2022	SELL	$5.06 - $26.46 $96,747 - $505,915	-19,120 Reduced 80.28%	4,698 $36,000
Q1 2022 May 12, 2022	SELL	$19.99 - $33.23 $1.17 Million - $1.95 Million	-58,658 Reduced 71.12%	23,818 $578,000
Q4 2021 Feb 10, 2022	BUY	$29.39 - $46.86 $461,775 - $736,264	15,712 Added 23.53%	82,476 $2.66 Million
Q3 2021 Nov 10, 2021	BUY	$35.91 - $50.5 $2.4 Million - $3.37 Million	66,764 New	66,764 $2.98 Million

Others Institutions Holding CCCC

# of Institutions

130

Shares Held

63.5M

Call Options Held

670K

Put Options Held

54.8K

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $193M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account